ES3033810T3 - Cancer treatments using combinations of cdk and erk inhibitors - Google Patents
Cancer treatments using combinations of cdk and erk inhibitorsInfo
- Publication number
- ES3033810T3 ES3033810T3 ES14872163T ES14872163T ES3033810T3 ES 3033810 T3 ES3033810 T3 ES 3033810T3 ES 14872163 T ES14872163 T ES 14872163T ES 14872163 T ES14872163 T ES 14872163T ES 3033810 T3 ES3033810 T3 ES 3033810T3
- Authority
- ES
- Spain
- Prior art keywords
- cancer
- antineoplastic
- cas
- pharmaceutically acceptable
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919597P | 2013-12-20 | 2013-12-20 | |
| PCT/US2014/071747 WO2015095840A1 (en) | 2013-12-20 | 2014-12-19 | Cancer treatments using combinations of cdk and erk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3033810T3 true ES3033810T3 (en) | 2025-08-08 |
Family
ID=53403797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14872163T Active ES3033810T3 (en) | 2013-12-20 | 2014-12-19 | Cancer treatments using combinations of cdk and erk inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US11013743B2 (OSRAM) |
| EP (2) | EP3082423B1 (OSRAM) |
| JP (1) | JP6678584B2 (OSRAM) |
| AU (1) | AU2014368927B2 (OSRAM) |
| ES (1) | ES3033810T3 (OSRAM) |
| WO (1) | WO2015095840A1 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009088990A1 (en) | 2008-01-04 | 2009-07-16 | Intellikine, Inc. | Certain chemical entities, compositions and methods |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| CA2890105C (en) | 2012-11-01 | 2023-03-21 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2017021177A1 (en) * | 2015-08-04 | 2017-02-09 | Universitat De Barcelona | Pharmaceutical combinations for use in the treatment of cancer |
| CN108135905A (zh) * | 2015-08-28 | 2018-06-08 | 诺华股份有限公司 | 用于治疗癌症的cdk4/6抑制剂lee011、mek1/2抑制剂曲美替尼以及可任选还包括pi3k抑制剂byl719的组合 |
| GB201605126D0 (en) * | 2016-03-24 | 2016-05-11 | Univ Nottingham | Inhibitors and their uses |
| US11865116B2 (en) * | 2016-03-24 | 2024-01-09 | Cothera Bioscience, Inc. | Treatment of cancer with TG02 |
| WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2018081204A1 (en) * | 2016-10-26 | 2018-05-03 | Li George Y | DEUTERATED N-(5-((4-ETHYLPIPERAZIN-1-YL)METHYL) PYRIDIN-2-YL)-5-FLUORO-4-(4-FLUORO-1-ISOPROPYL-2-METHYL-1H-BENZO[d]IMIDAZOL-6-YL)PYRIMIDIN-2-AMINE |
| US20210085663A1 (en) * | 2017-05-16 | 2021-03-25 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating cancer with atypical braf mutations |
| WO2018218633A1 (en) | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
| JP2019116429A (ja) * | 2017-12-26 | 2019-07-18 | 国立大学法人名古屋大学 | 抗ウイルス薬 |
| AU2019205821C1 (en) | 2018-01-08 | 2025-02-13 | Pharmacosmos Holding A/S | G1T38 superior dosage regimes |
| JP7698418B2 (ja) * | 2018-03-13 | 2025-06-25 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｅｇｆｒ活性化変異を有するがんを治療するための方法 |
| WO2019195959A1 (en) * | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| CN114366743A (zh) * | 2018-04-09 | 2022-04-19 | G1治疗公司 | 具有驱动致癌突变的癌症的治疗 |
| MX2021001749A (es) | 2018-08-13 | 2021-05-27 | Beijing Percans Oncology Co Ltd | Biomarcadores para terapia contra el cancer. |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| EP3923949A1 (en) * | 2019-02-15 | 2021-12-22 | Incyte Corporation | Cyclin-dependent kinase 2 biomarkers and uses thereof |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| PH12022550361A1 (en) | 2019-08-14 | 2023-02-27 | Incyte Corp | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| JP7693656B2 (ja) | 2019-10-11 | 2025-06-17 | インサイト・コーポレイション | Ｃｄｋ２阻害剤としての二環式アミン |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN117224545A (zh) * | 2023-09-26 | 2023-12-15 | 中国人民解放军陆军军医大学第二附属医院 | Aminopurvalanol A在制备治疗肺腺癌的药物中的应用 |
| WO2025111447A1 (en) * | 2023-11-21 | 2025-05-30 | Florida Atlantic University Board Of Trustees | Treatment of cancer with drug combinations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994021822A1 (en) | 1993-03-19 | 1994-09-29 | Sequenom, Inc. | Dna sequencing by mass spectrometry via exonuclease degradation |
| US6140053A (en) | 1996-11-06 | 2000-10-31 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
| US7439016B1 (en) | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
| CN101001857B (zh) * | 2002-01-22 | 2011-06-22 | 沃尼尔·朗伯有限责任公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 |
| US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| GB0320059D0 (en) | 2003-08-27 | 2003-10-01 | Solexa Ltd | A method of sequencing |
| US7354939B2 (en) * | 2004-05-14 | 2008-04-08 | Vertex Pharmaceuticals Incorporated | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto |
| US7582623B2 (en) | 2004-05-20 | 2009-09-01 | The Regents Of The University Of California | Photoactive metal nitrosyls for blood pressure regulation and cancer therapy |
| US20060228721A1 (en) | 2005-04-12 | 2006-10-12 | Leamon John H | Methods for determining sequence variants using ultra-deep sequencing |
| EP2155722B1 (en) * | 2007-06-05 | 2013-08-14 | Merck Sharp & Dohme Corp. | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer |
| US8685980B2 (en) * | 2008-08-22 | 2014-04-01 | Novartis Ag | Pyrrolopyrimidine compounds and their uses |
| US8877436B2 (en) | 2008-10-27 | 2014-11-04 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay on an automated platform |
| KR20120046018A (ko) | 2010-10-04 | 2012-05-09 | 삼성테크윈 주식회사 | 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출 |
| WO2012125848A2 (en) | 2011-03-16 | 2012-09-20 | Baylor College Of Medicine | A method for comprehensive sequence analysis using deep sequencing technology |
-
2014
- 2014-12-19 US US15/105,924 patent/US11013743B2/en active Active
- 2014-12-19 EP EP14872163.2A patent/EP3082423B1/en active Active
- 2014-12-19 AU AU2014368927A patent/AU2014368927B2/en active Active
- 2014-12-19 JP JP2016540553A patent/JP6678584B2/ja active Active
- 2014-12-19 EP EP24217401.9A patent/EP4512480A3/en active Pending
- 2014-12-19 ES ES14872163T patent/ES3033810T3/es active Active
- 2014-12-19 WO PCT/US2014/071747 patent/WO2015095840A1/en not_active Ceased
-
2020
- 2020-04-23 US US16/856,849 patent/US11135225B2/en active Active
-
2021
- 2021-08-30 US US17/460,743 patent/US11679112B2/en active Active
-
2023
- 2023-05-01 US US18/310,034 patent/US12076324B2/en active Active
-
2024
- 2024-07-29 US US18/787,389 patent/US20240374604A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4512480A3 (en) | 2025-05-07 |
| JP6678584B2 (ja) | 2020-04-22 |
| US20200297730A1 (en) | 2020-09-24 |
| US11013743B2 (en) | 2021-05-25 |
| EP3082423B1 (en) | 2024-12-11 |
| US20240374604A1 (en) | 2024-11-14 |
| US20210393637A1 (en) | 2021-12-23 |
| US11679112B2 (en) | 2023-06-20 |
| EP3082423A1 (en) | 2016-10-26 |
| US20240033267A1 (en) | 2024-02-01 |
| WO2015095840A1 (en) | 2015-06-25 |
| US11135225B2 (en) | 2021-10-05 |
| US12076324B2 (en) | 2024-09-03 |
| AU2014368927B2 (en) | 2018-10-25 |
| US20160317538A1 (en) | 2016-11-03 |
| AU2014368927A1 (en) | 2016-07-21 |
| EP3082423A4 (en) | 2017-09-20 |
| EP4512480A2 (en) | 2025-02-26 |
| JP2017502013A (ja) | 2017-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3033810T3 (en) | Cancer treatments using combinations of cdk and erk inhibitors | |
| ES2918375T3 (es) | Tratamientos contra el cáncer usando combinaciones de inhibidores de la ruta de PI3K/Akt y ERK | |
| ES2953311T3 (es) | Tratamientos contra el cáncer que usan combinaciones de inhibidores de ERK y MEK de tipo 2 | |
| WO2015095807A1 (en) | Cancer treatments using combinations of egfr and erk inhibitors | |
| US12419879B2 (en) | Combination therapy for the treatment of pancreatic cancer | |
| US20160310477A1 (en) | Cancer treatments using combinations of mek type 1 and erk inhibitors | |
| HK40120025A (en) | Cancer treatments using combinations of cdk and erk inhibitors | |
| HK1226252B (en) | Cancer treatments using combinations of cdk and erk inhibitors | |
| HK1226252A1 (en) | Cancer treatments using combinations of cdk and erk inhibitors | |
| HK1226350A1 (en) | Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors | |
| HK1226350B (en) | Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors |